[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100272046":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":32,"studyPopulation":11,"armGroups":33,"interventions":44,"overallOfficials":52,"centralContacts":60,"locations":66,"responsibleParty":458,"collaborators":460,"id":464,"slug":11,"hasResults":465,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":465,"sex":471,"minAge":472,"maxAge":11,"enrollmentInfo":473,"targetDuration":11,"studyType":476,"phases":477,"briefSummary":479,"conditions":480,"keywords":11,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":491},{"fullName":5,"class":6},"Canadian Cancer Trials Group","NETWORK",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Overall survival",null,"7 years",[14,16,18,20,22,24],{"measure":15,"description":11,"timeFrame":12},"Progression-free survival using RECIST 1.1 \u002F Immune-Related RECIST (irRECIST)",{"measure":17,"description":11,"timeFrame":12},"Response rate using RECIST 1.1 \u002F Immune-Related RECIST (irRECIST)",{"measure":19,"description":11,"timeFrame":12},"Duration of response using RECIST 1.1 \u002F Immune-Related RECIST (irRECIST)",{"measure":21,"description":11,"timeFrame":12},"Number and severity of adverse events using CTCAE v 4.0",{"measure":23,"description":11,"timeFrame":12},"Quality of Life measured by EORTC QLQ-C30",{"measure":25,"description":11,"timeFrame":12},"Economic evaluation consisting of both healthcare utilization and health utilities measured by the EQ-5D questionnaire",{"allocation":27,"interventionModel":28,"interventionModelDescription":11,"primaryPurpose":29,"observationalModel":11,"timePerspective":11,"maskingInfo":30},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":31,"maskingDescription":11,"whoMasked":11},"NONE","The standard or usual treatment for this disease is to receive treatment with a class of agents known as PD-1 inhibitors, or also with the names anti-PD-1 therapy, immunotherapy and checkpoint inhibitors. PD-1 inhibitors turn on the immune system, so that it can fight the cancer cells in the body. Clinical trials have shown that PD-1 inhibitors (such as pembrolizumab and nivolumab) can shrink tumours and extend the life of patients with melanoma.\n\nTo-date, PD-1 inhibitors have been given to patients with melanoma continuously (non-stop), for as long as they remain beneficial, for up to a total duration of 2 years. The 2 year duration was chosen because doctors thought it was reasonable, and has been adopted as the standard or usual duration because it was shown to work in clinical trials. However, some recent observations suggest that PD-1 inhibitors may work just as well if they are given for a shorter time and\u002For in an intermittent schedule. Intermittent means to take breaks from receiving the drug when, and for as long as, the melanoma is better.\n\nThe investigators doing this study are interested to find out whether patients with melanoma live as long when the PD-1 inhibitors are given continuously (non-stop) or in an intermittent schedule (taking breaks). If the two ways of giving the treatment were to be shown to be just as good, benefits of an intermittent schedule may include less clinic visits and side effects, better quality of life, and less cost over time for the Health Care System. However, this is not known at present.",[34,40],{"label":35,"type":36,"description":37,"interventionNames":38},"Arm 1: Intermittent PD-1 Inhibitor therapy","ACTIVE_COMPARATOR","Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.",[39],"Drug: Intermittent PD-1 inhibitor therapy",{"label":41,"type":36,"description":37,"interventionNames":42},"Arm 2: Continuous PD-1 Inhibitor therapy",[43],"Drug: Continuous PD-1 inhibitor therapy",[45,49],{"type":46,"name":47,"description":11,"armGroupLabels":48,"otherNames":11},"DRUG","Intermittent PD-1 inhibitor therapy",[35],{"type":46,"name":50,"description":11,"armGroupLabels":51,"otherNames":11},"Continuous PD-1 inhibitor therapy",[41],[53,57],{"name":54,"affiliation":55,"role":56},"Xinni Song","Ottawa Hospital Research Institute","STUDY_CHAIR",{"name":58,"affiliation":59,"role":56},"Tara Baetz","Cancer Centre of Southeastern Ontario at Kingston",[61],{"name":62,"role":63,"phone":64,"phoneExt":11,"email":65},"Janet Dancey","CONTACT","613-533-6430","jdancey@ctg.queensu.ca",[67,78,92,104,116,131,143,155,168,180,192,204,220,234,248,258,272,286,299,313,327,341,354,368,381,393,406,417,431,445],{"facility":68,"status":69,"city":70,"state":71,"zip":72,"country":73,"countryCode":74,"cosmosGeoPoint":11,"geoPoint":11,"contacts":75},"Mildura Base Public Hospital","RECRUITING","Victoria","Mildura","3500","Australia","AU",[76],{"name":77,"role":63,"phone":11,"phoneExt":11,"email":11},"Jose Leal",{"facility":79,"status":69,"city":80,"state":81,"zip":82,"country":73,"countryCode":74,"cosmosGeoPoint":83,"geoPoint":88,"contacts":89},"Coffs Habour Health Campus - NCCI","Coffs Harbour","New South Wales","2450",{"type":84,"coordinates":85},"Point",[86,87],153.11351,-30.29626,{"lat":87,"lon":86},[90],{"name":91,"role":63,"phone":11,"phoneExt":11,"email":11},"Karen Briscoe",{"facility":93,"status":69,"city":94,"state":81,"zip":95,"country":73,"countryCode":74,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Calvary Mater Newcastle Hospital","Waratah","2298",{"type":84,"coordinates":97},[98,99],151.72647,-32.90667,{"lat":99,"lon":98},[102],{"name":103,"role":63,"phone":11,"phoneExt":11,"email":11},"Ina Nordman",{"facility":105,"status":69,"city":106,"state":81,"zip":107,"country":73,"countryCode":74,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Westmead Hospital","Westmead","2145",{"type":84,"coordinates":109},[110,111],150.98768,-33.80383,{"lat":111,"lon":110},[114],{"name":115,"role":63,"phone":11,"phoneExt":11,"email":11},"Matteo Carlino",{"facility":117,"status":69,"city":118,"state":119,"zip":120,"country":73,"countryCode":74,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Sunshine Coast University Hospital","Birtinya","Queensland","4575",{"type":84,"coordinates":122},[123,124],153.11913,-26.74322,{"lat":124,"lon":123},[127],{"name":128,"role":63,"phone":129,"phoneExt":130,"email":11},"Mary Wagih Azer","7 520-0200","651",{"facility":132,"status":69,"city":133,"state":119,"zip":134,"country":73,"countryCode":74,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Cairns Hospital","Cairns","4870",{"type":84,"coordinates":136},[137,138],145.76613,-16.92366,{"lat":138,"lon":137},[141],{"name":142,"role":63,"phone":11,"phoneExt":11,"email":11},"Megan Lyle",{"facility":144,"status":69,"city":145,"state":119,"zip":146,"country":73,"countryCode":74,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Gold Coast University Hospital","Southport","4215",{"type":84,"coordinates":148},[149,150],153.39796,-27.96724,{"lat":150,"lon":149},[153],{"name":154,"role":63,"phone":11,"phoneExt":11,"email":11},"Marcin Dzienis",{"facility":156,"status":69,"city":157,"state":158,"zip":159,"country":73,"countryCode":74,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"The Queen Elizabeth Hospital","Woodville","South A.","5011",{"type":84,"coordinates":161},[162,163],138.54291,-34.877,{"lat":163,"lon":162},[166],{"name":167,"role":63,"phone":11,"phoneExt":11,"email":11},"Rachel Roberts-thomson",{"facility":169,"status":69,"city":170,"state":70,"zip":171,"country":73,"countryCode":74,"cosmosGeoPoint":172,"geoPoint":176,"contacts":177},"Monash Medical Centre","Clayton","3168",{"type":84,"coordinates":173},[174,175],145.11667,-37.91667,{"lat":175,"lon":174},[178],{"name":179,"role":63,"phone":11,"phoneExt":11,"email":11},"Muhammad Alamgeer",{"facility":181,"status":69,"city":182,"state":70,"zip":183,"country":73,"countryCode":74,"cosmosGeoPoint":184,"geoPoint":188,"contacts":189},"Alfred Hospital","Melbourne","3004",{"type":84,"coordinates":185},[186,187],144.96332,-37.814,{"lat":187,"lon":186},[190],{"name":191,"role":63,"phone":11,"phoneExt":11,"email":11},"Mark Shackleton",{"facility":193,"status":69,"city":194,"state":11,"zip":195,"country":73,"countryCode":74,"cosmosGeoPoint":196,"geoPoint":200,"contacts":201},"Royal Brisbane and Womens Hospital","Herston","4029",{"type":84,"coordinates":197},[198,199],153.01852,-27.44453,{"lat":199,"lon":198},[202],{"name":203,"role":63,"phone":11,"phoneExt":11,"email":11},"Melissa Eastgate",{"facility":205,"status":69,"city":206,"state":207,"zip":208,"country":209,"countryCode":210,"cosmosGeoPoint":211,"geoPoint":215,"contacts":216},"Cross Cancer Institute","Edmonton","Alberta","T6G 1Z2","Canada","CA",{"type":84,"coordinates":212},[213,214],-113.46871,53.55014,{"lat":214,"lon":213},[217],{"name":218,"role":63,"phone":219,"phoneExt":11,"email":11},"John Walker","780 432-8340",{"facility":221,"status":69,"city":222,"state":223,"zip":224,"country":209,"countryCode":210,"cosmosGeoPoint":225,"geoPoint":229,"contacts":230},"BCCA - Surrey","Surrey","British Columbia","V3V 1Z2",{"type":84,"coordinates":226},[227,228],-122.82509,49.10635,{"lat":228,"lon":227},[231],{"name":232,"role":63,"phone":233,"phoneExt":11,"email":11},"Christopher Lee","604 930-4017",{"facility":235,"status":69,"city":236,"state":223,"zip":237,"country":209,"countryCode":210,"cosmosGeoPoint":238,"geoPoint":242,"contacts":243},"BCCA - Vancouver","Vancouver","V5Z 4E6",{"type":84,"coordinates":239},[240,241],-123.11934,49.24966,{"lat":241,"lon":240},[244],{"name":245,"role":63,"phone":246,"phoneExt":247,"email":11},"Kerry J. Savage","604 877-6000","2641",{"facility":249,"status":69,"city":70,"state":223,"zip":250,"country":209,"countryCode":210,"cosmosGeoPoint":251,"geoPoint":255,"contacts":256},"BCCA - Victoria","V8R 6V5",{"type":84,"coordinates":252},[253,254],-123.35155,48.4359,{"lat":254,"lon":253},[257],{"name":58,"role":63,"phone":11,"phoneExt":11,"email":11},{"facility":259,"status":69,"city":260,"state":261,"zip":262,"country":209,"countryCode":210,"cosmosGeoPoint":263,"geoPoint":267,"contacts":268},"Horizon Health Network","Fredericton","New Brunswick","E3B 5N5",{"type":84,"coordinates":264},[265,266],-66.66558,45.94541,{"lat":266,"lon":265},[269],{"name":270,"role":63,"phone":271,"phoneExt":11,"email":11},"M. Saleem Raza","506 447-4095",{"facility":273,"status":69,"city":274,"state":275,"zip":276,"country":209,"countryCode":210,"cosmosGeoPoint":277,"geoPoint":281,"contacts":282},"Royal Victoria Regional Health Centre","Barrie","Ontario","L4M 6M2",{"type":84,"coordinates":278},[279,280],-79.66634,44.40011,{"lat":280,"lon":279},[283],{"name":284,"role":63,"phone":285,"phoneExt":11,"email":11},"Jason Yu","705 728-9090",{"facility":287,"status":69,"city":288,"state":275,"zip":289,"country":209,"countryCode":210,"cosmosGeoPoint":290,"geoPoint":294,"contacts":295},"Health Sciences North","Greater Sudbury","P3E 5J1",{"type":84,"coordinates":291},[292,293],-80.99001,46.49,{"lat":293,"lon":292},[296],{"name":297,"role":63,"phone":298,"phoneExt":11,"email":11},"Lacey Pitre","705 522-6237",{"facility":300,"status":69,"city":301,"state":275,"zip":302,"country":209,"countryCode":210,"cosmosGeoPoint":303,"geoPoint":307,"contacts":308},"Juravinski Cancer Centre at Hamilton Health Sciences","Hamilton","L8V 5C2",{"type":84,"coordinates":304},[305,306],-79.84963,43.25011,{"lat":306,"lon":305},[309],{"name":310,"role":63,"phone":311,"phoneExt":312,"email":11},"Elaine McWhirter","905 387-9495","64609",{"facility":314,"status":69,"city":315,"state":275,"zip":316,"country":209,"countryCode":210,"cosmosGeoPoint":317,"geoPoint":321,"contacts":322},"Kingston Health Sciences Centre","Kingston","K7L 2V7",{"type":84,"coordinates":318},[319,320],-76.48098,44.22976,{"lat":320,"lon":319},[323],{"name":324,"role":63,"phone":325,"phoneExt":326,"email":11},"Mihaela Mates","613 549-2631","77725",{"facility":328,"status":69,"city":329,"state":275,"zip":330,"country":209,"countryCode":210,"cosmosGeoPoint":331,"geoPoint":335,"contacts":336},"Waterloo Regional Health Network (WRHN)","Kitchener","N2G 1G3",{"type":84,"coordinates":332},[333,334],-80.5112,43.42537,{"lat":334,"lon":333},[337],{"name":338,"role":63,"phone":339,"phoneExt":340,"email":11},"Gregory J. Knight","519 749-4370","5262",{"facility":342,"status":69,"city":343,"state":275,"zip":344,"country":209,"countryCode":210,"cosmosGeoPoint":345,"geoPoint":349,"contacts":350},"London Health Sciences Centre Research Inc.","London","N6A 5W9",{"type":84,"coordinates":346},[347,348],-81.23304,42.98339,{"lat":348,"lon":347},[351],{"name":352,"role":63,"phone":353,"phoneExt":11,"email":11},"John Lenehan","519 685-8640",{"facility":355,"status":69,"city":356,"state":275,"zip":357,"country":209,"countryCode":210,"cosmosGeoPoint":358,"geoPoint":362,"contacts":363},"Trillium Health Partners - Credit Valley Hospital","Mississauga","L5M 2N1",{"type":84,"coordinates":359},[360,361],-79.6583,43.5789,{"lat":361,"lon":360},[364],{"name":365,"role":63,"phone":366,"phoneExt":367,"email":11},"Sudha Rajagopal","905 813-1100","5135",{"facility":369,"status":69,"city":370,"state":275,"zip":371,"country":209,"countryCode":210,"cosmosGeoPoint":372,"geoPoint":376,"contacts":377},"Lakeridge Health Oshawa","Oshawa","L1G 2B9",{"type":84,"coordinates":373},[374,375],-78.84957,43.90012,{"lat":375,"lon":374},[378],{"name":379,"role":63,"phone":380,"phoneExt":11,"email":11},"Rama Koneru","905 576-8711",{"facility":55,"status":69,"city":382,"state":275,"zip":383,"country":209,"countryCode":210,"cosmosGeoPoint":384,"geoPoint":388,"contacts":389},"Ottawa","K1H 8L6",{"type":84,"coordinates":385},[386,387],-75.69812,45.41117,{"lat":387,"lon":386},[390],{"name":54,"role":63,"phone":391,"phoneExt":392,"email":11},"613 737-7700","70208",{"facility":394,"status":69,"city":395,"state":275,"zip":396,"country":209,"countryCode":210,"cosmosGeoPoint":397,"geoPoint":401,"contacts":402},"Odette Cancer Centre","Toronto","M4N 3M5",{"type":84,"coordinates":398},[399,400],-79.39864,43.70643,{"lat":400,"lon":399},[403],{"name":404,"role":63,"phone":405,"phoneExt":11,"email":11},"Teresa M. Petrella","416 480-5145",{"facility":407,"status":69,"city":395,"state":275,"zip":408,"country":209,"countryCode":210,"cosmosGeoPoint":409,"geoPoint":411,"contacts":412},"University Health Network","M5G 2M9",{"type":84,"coordinates":410},[399,400],{"lat":400,"lon":399},[413],{"name":414,"role":63,"phone":415,"phoneExt":416,"email":11},"Marcus Butler","416 946-4501","5485",{"facility":418,"status":69,"city":419,"state":420,"zip":421,"country":209,"countryCode":210,"cosmosGeoPoint":422,"geoPoint":426,"contacts":427},"The Research Institute of the McGill University","Montreal","Quebec","H4A 3J1",{"type":84,"coordinates":423},[424,425],-73.58781,45.50884,{"lat":425,"lon":424},[428],{"name":429,"role":63,"phone":430,"phoneExt":11,"email":11},"Catalin Mihalcioiu","514 934-1934",{"facility":432,"status":69,"city":433,"state":434,"zip":435,"country":209,"countryCode":210,"cosmosGeoPoint":436,"geoPoint":440,"contacts":441},"Allan Blair Cancer Centre","Regina","Saskatchewan","S4T 7T1",{"type":84,"coordinates":437},[438,439],-104.6178,50.45008,{"lat":439,"lon":438},[442],{"name":443,"role":63,"phone":444,"phoneExt":11,"email":11},"Mussawar Iqbal","306 766-2691",{"facility":446,"status":69,"city":447,"state":434,"zip":448,"country":209,"countryCode":210,"cosmosGeoPoint":449,"geoPoint":453,"contacts":454},"Saskatoon Cancer Centre","Saskatoon","S7N 4H4",{"type":84,"coordinates":450},[451,452],-106.66892,52.13238,{"lat":452,"lon":451},[455],{"name":456,"role":63,"phone":457,"phoneExt":11,"email":11},"Tahir Abbas","306 655-2710",{"type":459,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[461],{"name":462,"class":463},"Melanoma and Skin Cancer Trials Limited","OTHER","100272046",false,"NCT02821013","Duration of Anti-PD-1 Therapy in Metastatic Melanoma","A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma","STOP-GAP","Minimum age 18 or as specified in the Product Monograph and eligible for public funding.\n\nInclusion Criteria:\n\n* Histologically confirmed melanoma that is unresectable \u002F metastatic (stage III or stage IV).\n* Eligible to receive treatment with a government approved and publically-funded PD-1 inhibitor, according to the guidance \u002F indications described in the Product Monograph \u002F Provincial Formulary.\n* Patients must have evidence of unresectable \u002F metastatic disease, that is considered evaluable by the investigator and can be followed, but measurable disease is not mandatory.\n* Patients with brain metastases are allowed, provided they are stable according to the following definitions:\n\n  1. Without evidence of progression for at least four weeks prior to randomization and have no evidence of new or enlarging brain metastases.\n  2. Treated with surgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases.\n  3. Treated with stereotactic radiosurgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases.\n* Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life and health utility questionnaires in either English or French. The baseline assessment must be completed within required timelines, prior to randomization. Inability (lack of comprehension in English or French, or other equivalent reason such as cognitive issues or lack of competency) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible.\n* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate.\n* Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.\n* Patients must be randomized prior to the start of, or within 16 weeks from, the initiation of PD-1 inhibitor treatment. For patients who are being randomized before the start of treatment, the PD-1 inhibitor should be started within 5 working days after randomization. Patients who initiate treatment with combination anti-PD-1 and anti-CTLA-4 therapies who experience toxicity may be randomized at the time prior to starting single-agent PD-1 inhibitor. Repeat imaging must be done within 50 days prior to randomization to ensure the patient has no evidence of disease progression\n\nExclusion Criteria:\n\n* Patients not willing to stop anti-PD-1 therapy, if randomized to the intermittent arm.\n* Patients with any contraindications to PD-1 inhibitors, as described in the Product Monograph or Provincial Formulary, and\u002For not eligible to receive anti-PD-1 therapy.","ALL","18 Years",{"count":474,"type":475},614,"ESTIMATED","INTERVENTIONAL",[478],"PHASE3","The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.",[481],"Unresectable\u002FMetastatic Melanoma","2026-06-08",{"date":484,"type":485},"2026-06-09","ACTUAL",{"date":487,"type":485},"2016-10-31",{"date":489,"type":475},"2029-12-31",{"name":5,"class":6},30]